Observational studyBMC urology2026
Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.
Observational study in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite apparent cure after treatment of localized prostate cancer (PC), a significant proportion of patients who undergo radical prostatectomy (RP) or radiotherapy (RT) will experience biochemical recurrence (BCR) within 10 years. This study was conducted to evaluate the main aspects of BCR after primary definitive treatment in a real-world setting in Brazil.
methodsIn this retrospective, single-center, observational cohort study, data were extracted from electronic medical records of patients aged ≥18 years with PC, treated at one clinical site in Brazil, who underwent definitive curative-intent treatment during January 1, 2005-December 31, 2018. The primary objective was to estimate 5-year BCR rate, defined per European Association of Urology (EAU) criteria as PSA >0.2 ng/mL after RP, or PSA nadir + 2 ng/mL above nadir after RT.
resultsOf 971 patients included, 131 (13.5%) experienced BCR within 5 years. Of these, 48 (36.6%) patients underwent RP as primary definitive treatment; 33 (25.2%) underwent RT. Of 5-year BCR patients, 40 (30.5%) underwent computed tomography, and 27 (20.6%) underwent bone scintigraphy. In addition, 69 (52.7%) were deemed non-metastatic hormone-sensitive PC (nmHSPC; 29 high risk, 33 low risk) and 30 (22.9%) were diagnosed with metastatic hormone-sensitive PC (mHSPC). The median time from definitive treatment to BCR was shorter for patients with high-risk BCR nmHSPC than low-risk BCR (27.7 vs 37.0 months, respectively).
conclusionsThis retrospective cohort study provides the first real-world characterisation of BCR after definitive treatment in Brazil, demonstrating that patients with high-risk nmHSPC BCR experienced earlier recurrence and shorter time to first-line treatment than low-risk patients. These data highlight the need for improved post-treatment monitoring and earlier therapeutic intervention in high-risk BCR populations in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.